{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:32:06Z","timestamp":1761514326274,"version":"3.40.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00125-018-4808-7","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T12:54:51Z","timestamp":1546692891000},"page":"578-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A future for CD3 antibodies in immunotherapy of type 1 diabetes"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1328-2786","authenticated-orcid":false,"given":"Lucienne","family":"Chatenoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"issue":"3","key":"4808_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.smim.2011.07.009","volume":"23","author":"JF Bach","year":"2011","unstructured":"Bach JF, Chatenoud L (2011) A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Semin Immunol 23(3):174\u2013181. https:\/\/doi.org\/10.1016\/j.smim.2011.07.009","journal-title":"Semin Immunol"},{"issue":"8420","key":"4808_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(85)91964-6","volume":"1","author":"R Assan","year":"1985","unstructured":"Assan R, Feutren G, Debray-sachs M et al (1985) Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1(8420):67\u201371","journal-title":"Lancet"},{"issue":"4643","key":"4808_CR3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.6367043","volume":"223","author":"CR Stiller","year":"1984","unstructured":"Stiller CR, Dupre J, Gent M et al (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223(4643):1362\u20131367. https:\/\/doi.org\/10.1126\/science.6367043","journal-title":"Science"},{"issue":"11","key":"4808_CR4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/diab.37.11.1574","volume":"37","author":"The Canadian-European Randomized Control Trial Group","year":"1988","unstructured":"The Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37(11):1574\u20131582. https:\/\/doi.org\/10.2337\/diab.37.11.1574","journal-title":"Diabetes"},{"issue":"4","key":"4808_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1084\/jem.183.4.1561","volume":"183","author":"J Tian","year":"1996","unstructured":"Tian J, Atkinson MA, Clare Salzler M et al (1996) Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183(4):1561\u20131567. https:\/\/doi.org\/10.1084\/jem.183.4.1561","journal-title":"J Exp Med"},{"key":"4808_CR6","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4049\/jimmunol.163.3.1178","volume":"163","author":"R Tisch","year":"1999","unstructured":"Tisch R, Wang B, Serreze DV (1999) Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 163:1178\u20131187","journal-title":"J Immunol"},{"issue":"1","key":"4808_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1073\/pnas.91.1.123","volume":"91","author":"L Chatenoud","year":"1994","unstructured":"Chatenoud L, Thervet E, Primo J et al (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91(1):123\u2013127. https:\/\/doi.org\/10.1073\/pnas.91.1.123","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4808_CR8","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","volume":"158","author":"L Chatenoud","year":"1997","unstructured":"Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158:2947\u20132954","journal-title":"J Immunol"},{"issue":"9","key":"4808_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/nm924","volume":"9","author":"M Belghith","year":"2003","unstructured":"Belghith M, Bluestone JA, Barriot S et al (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9(9):1202\u20131208. https:\/\/doi.org\/10.1038\/nm924","journal-title":"Nat Med"},{"issue":"8","key":"4808_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nri2134","volume":"7","author":"L Chatenoud","year":"2007","unstructured":"Chatenoud L, Bluestone JA (2007) CD3-specific antibodies : a portal to the treatment of autoimmunity. Nat Rev Immunol 7(8):622\u2013632. https:\/\/doi.org\/10.1038\/nri2134","journal-title":"Nat Rev Immunol"},{"issue":"9651","key":"4808_CR11","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","volume":"372","author":"K Nanto-Salonen","year":"2008","unstructured":"Nanto-Salonen K, Kupila A, Simell S et al (2008) Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372(9651):1746\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(08)61309-4","journal-title":"Lancet"},{"key":"4808_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","volume":"346","author":"J Skyler","year":"2002","unstructured":"Skyler J (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus Diabetes Prevention Trial-Type 1 Diabetes Study Group. N Engl J Med 346:1685\u20131691","journal-title":"N Engl J Med"},{"issue":"19","key":"4808_CR13","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"JP Krischer","year":"2017","unstructured":"Krischer JP, Schatz DA, Bundy B et al (2017) Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318(19):1891\u20131902. https:\/\/doi.org\/10.1001\/jama.2017.17070","journal-title":"JAMA"},{"issue":"5","key":"4808_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa1107096","volume":"366","author":"J Ludvigsson","year":"2012","unstructured":"Ludvigsson J, Krisky D, Casas R et al (2012) GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366(5):433\u2013442. https:\/\/doi.org\/10.1056\/NEJMoa1107096","journal-title":"N Engl J Med"},{"issue":"9788","key":"4808_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","volume":"378","author":"DK Wherrett","year":"2011","unstructured":"Wherrett DK, Bundy B, Becker DJ et al (2011) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378(9788):319\u2013327. https:\/\/doi.org\/10.1016\/S0140-6736(11)60895-7","journal-title":"Lancet"},{"issue":"8","key":"4808_CR16","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI81722","volume":"125","author":"MR Rigby","year":"2015","unstructured":"Rigby MR, Harris KM, Pinckney A et al (2015) Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125(8):3285\u20133296. https:\/\/doi.org\/10.1172\/JCI81722","journal-title":"J Clin Invest"},{"issue":"6","key":"4808_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","volume":"59","author":"SE Gitelman","year":"2016","unstructured":"Gitelman SE, Gottlieb PA, Felner EI et al (2016) Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia 59(6):1153\u20131161. https:\/\/doi.org\/10.1007\/s00125-016-3917-4","journal-title":"Diabetologia"},{"issue":"6","key":"4808_CR18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","volume":"54","author":"KC Herold","year":"2005","unstructured":"Herold KC, Gitelman SE, Masharani U et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54(6):1763\u20131769. https:\/\/doi.org\/10.2337\/diabetes.54.6.1763","journal-title":"Diabetes"},{"issue":"22","key":"4808_CR19","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346(22):1692\u20131698. https:\/\/doi.org\/10.1056\/NEJMoa012864","journal-title":"N Engl J Med"},{"issue":"25","key":"4808_CR20","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"B Keymeulen","year":"2005","unstructured":"Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352(25):2598\u20132608. https:\/\/doi.org\/10.1056\/NEJMoa043980","journal-title":"N Engl J Med"},{"issue":"4","key":"4808_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","volume":"53","author":"B Keymeulen","year":"2010","unstructured":"Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53(4):614\u2013623. https:\/\/doi.org\/10.1007\/s00125-009-1644-9","journal-title":"Diabetologia"},{"issue":"22","key":"4808_CR22","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","volume":"361","author":"MD Pescovitz","year":"2009","unstructured":"Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143\u20132152. https:\/\/doi.org\/10.1056\/NEJMoa0904452","journal-title":"N Engl J Med"},{"issue":"9789","key":"4808_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789):412\u2013419. https:\/\/doi.org\/10.1016\/S0140-6736(11)60886-6","journal-title":"Lancet"},{"issue":"4","key":"4808_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2337\/dc13-0604","volume":"37","author":"T Orban","year":"2014","unstructured":"Orban T, Bundy B, Becker DJ et al (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37(4):1069\u20131075. https:\/\/doi.org\/10.2337\/dc13-0604","journal-title":"Diabetes Care"},{"issue":"11","key":"4808_CR25","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.2337\/db13-0345","volume":"62","author":"KC Herold","year":"2013","unstructured":"Herold KC, Gitelman SE, Ehlers MR et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766\u20133774. https:\/\/doi.org\/10.2337\/db13-0345","journal-title":"Diabetes"},{"key":"4808_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60931-8","volume":"378","author":"N Sherry","year":"2011","unstructured":"Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:412\u2013419","journal-title":"Lancet"},{"key":"4808_CR27","doi-asserted-by":"publisher","unstructured":"Perdigoto AL, Preston-Hurlburt P, Clark P et al (2018) Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-018-4786-9","DOI":"10.1007\/s00125-018-4786-9"},{"issue":"5","key":"4808_CR28","doi-asserted-by":"publisher","first-page":"eaai7793","DOI":"10.1126\/sciimmunol.aai7793","volume":"1","author":"SA Long","year":"2016","unstructured":"Long SA, Thorpe J, DeBerg HA et al (2016) Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol 1(5):eaai7793. https:\/\/doi.org\/10.1126\/sciimmunol.aai7793","journal-title":"Sci Immunol"},{"key":"4808_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cellimm.2017.07.007","volume":"319","author":"SA Long","year":"2017","unstructured":"Long SA, Thorpe J, Herold KC et al (2017) Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol 319:3\u20139. https:\/\/doi.org\/10.1016\/j.cellimm.2017.07.007","journal-title":"Cell Immunol"},{"issue":"1","key":"4808_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/eji.201545708","volume":"46","author":"JE Tooley","year":"2016","unstructured":"Tooley JE, Vudattu N, Choi J et al (2016) Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol 46(1):230\u2013241. https:\/\/doi.org\/10.1002\/eji.201545708","journal-title":"Eur J Immunol"},{"issue":"12","key":"4808_CR31","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1084\/jem.20061577","volume":"203","author":"BT Fife","year":"2006","unstructured":"Fife BT, Guleria I, Gubbels Bupp M et al (2006) Insulin-induced remission in new-onset NOD mice is maintained by the PD-1\u2013PD-L1 pathway. J Exp Med 203(12):2737\u20132747. https:\/\/doi.org\/10.1084\/jem.20061577","journal-title":"J Exp Med"},{"key":"4808_CR32","doi-asserted-by":"publisher","first-page":"e08133","DOI":"10.7554\/eLife.08133","volume":"5","author":"M Baas","year":"2016","unstructured":"Baas M, Besan\u00e7on A, Goncalves T et al (2016) TGF\u03b2-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance. Elife 5:e08133. https:\/\/doi.org\/10.7554\/eLife.08133","journal-title":"Elife"},{"key":"4808_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fimmu.2017.00218","volume":"8","author":"A Besan\u00e7on","year":"2017","unstructured":"Besan\u00e7on A, Baas M, Goncalves T et al (2017) The induction and maintenance of transplant tolerance engages both regulatory and anergic CD4+ T cells. Front Immunol 8:218","journal-title":"Front Immunol"},{"issue":"12","key":"4808_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMra020100","volume":"347","author":"JF Bach","year":"2002","unstructured":"Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347(12):911\u2013920. https:\/\/doi.org\/10.1056\/NEJMra020100","journal-title":"N Engl J Med"},{"issue":"2","key":"4808_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nri.2017.111","volume":"18","author":"JF Bach","year":"2018","unstructured":"Bach JF (2018) The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol 18(2):105\u2013120. https:\/\/doi.org\/10.1038\/nri.2017.111","journal-title":"Nat Rev Immunol"},{"key":"4808_CR36","doi-asserted-by":"publisher","unstructured":"Patterson CC, Harjutsalo V, Rosenbauer J et al (2018) Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-018-4763-3","DOI":"10.1007\/s00125-018-4763-3"},{"issue":"8","key":"4808_CR37","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2337\/db12-1175","volume":"62","author":"C Hu","year":"2013","unstructured":"Hu C, Ding H, Zhang X et al (2013) Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes 62(8):2849\u20132858. https:\/\/doi.org\/10.2337\/db12-1175","journal-title":"Diabetes"},{"issue":"6","key":"4808_CR38","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.2337\/db11-1304","volume":"61","author":"AA Mamchak","year":"2012","unstructured":"Mamchak AA, Manenkova Y, Leconet W et al (2012) Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes 61(6):1490\u20131499. https:\/\/doi.org\/10.2337\/db11-1304","journal-title":"Diabetes"},{"issue":"10","key":"4808_CR39","doi-asserted-by":"publisher","first-page":"e77296","DOI":"10.1371\/journal.pone.0077296","volume":"8","author":"S You","year":"2013","unstructured":"You S, Piali L, Kuhn C et al (2013) Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PLoS One 8(10):e77296. https:\/\/doi.org\/10.1371\/journal.pone.0077296","journal-title":"PLoS One"},{"issue":"2","key":"4808_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00125-017-4459-0","volume":"61","author":"A Besan\u00e7on","year":"2018","unstructured":"Besan\u00e7on A, Goncalves T, Valette F et al (2018) Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Diabetologia 61(2):389\u2013398. https:\/\/doi.org\/10.1007\/s00125-017-4459-0","journal-title":"Diabetologia"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-018-4808-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:21:54Z","timestamp":1694542914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-018-4808-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1007\/s00125-018-4808-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"5 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has received an honorarium from Provention Bio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}